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mating quality-adjusted life years (QALYs) for use in an incre-
mental cost-utility analysis.
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OBJECTIVE: To quantify the effect on adherence likelihood of
patients’ preferences for short-term outcomes and side effects of
bipolar disorder treatments. METHODS: Patients with bipolar
disorder (n = 469) completed a choice-format conjoint or stated-
preference, web-enabled questionnaire that included a series of
11 hypothetical treatment choices. Each treatment alternative
speciﬁed and varied the frequency and severity of manic episodes
and the frequency and severity of depressed episodes, in addition
to weight gain, cognitive difﬁculties, fatigue, and the risk of
developing a life-threatening side effect. The patient’s current
treatment was included as one of 3 alternatives in 6 of the choice
tasks. Each choice task was followed by a question on likely
adherence to the chosen treatment. RESULTS: Patients preferred
milder episodes of mania and depression. Reduced frequency 
of manic and depressive episodes contributes signiﬁcantly to
patients’ satisfaction with treatments. The likelihood of choos-
ing a treatment with an interval between mania episodes of 4–6
months is 2.5 times greater than the likelihood of choosing a
treatment with an interval between manic episodes of 2–3
months. Patients were willing to sacriﬁce symptom control to
avoid signiﬁcant weight gain or cognitive effects. For example,
the reduction in patient satisfaction from a 10–20 lb gain in
weight compared to a 2–10 lb weight gain was similar to the dif-
ference in patient satisfaction between a severe and mild manic
episode. Fatigue and risk of a life-threatening side effect were the
least important attributes. Factors that reduce likely adherence
are rapid cycling, signiﬁcant weight-gain experience, and severe
fatigue or cognition problems. CONCLUSION: In this study
bipolar patients were willing to sacriﬁce mood-control beneﬁts
of therapy to avoid side effects, particularly weight gain and cog-
nitive side effects. Preferred treatments encourage quantitatively
signiﬁcant improvements in stated adherence and thus should
improve long-term treatment outcomes.
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OBJECTIVES: New anticoagulant drugs, alternative to vitamin
K antagonist (VKA) are currently under clinical evaluation.
Patients’ preferences should be considered in the development 
of new therapeutic strategies. Objective of this study was to 
elicit patients’ preferences on different treatment options.
METHODS: A conjoint analysis exercise, a technique for estab-
lishing the relative importance of different characteristics in the
provision of a good or service, was applied to 96 patients on
stable treatment with VKA followed by our anticoagulation
clinic. Ninety-four patients (49 male 52,1%; mean age 57 ds =
13) completed the questionnaire. Patients had to choose between
two different scenarios in 9 pair-wise comparisons. The attrib-
utes considered had previously been selected using an ad-hoc
questionnaire administered to a sample of 20 patients and 6
physicians. The following attributes were selected: cost of treat-
ment for the patient (€0 vs. €15 vs. €75/month), route and
number of administrations, monitoring frequency, interactions
with drugs/food (attention required vs. not required), dose
adjustment (required vs. not required), minor bleeding (few vs.
no). RESULTS: The variable “cost” was a signiﬁcant determi-
nant in patients’ choice. A monetary value could be assigned 
to each attribute. A signiﬁcant monetary discrimination was
reached for all attributes, except for dose adjustment. Patients
are willing to pay per month: €62 for once/daily administration
tablets vs. one subcutaneous weekly injection; €44 for once/daily
administration tablets vs. two/daily administration tablets; €26
for once/monthly vs. twice/monthly visits; €22 for each 6 month
vs. once/monthly visits; €22 for a drug which requires no atten-
tion to the interaction with other drugs/food; €14 for a drug
without risk of minor bleeding. CONCLUSIONS: To our knowl-
edge, our study is the ﬁrst to elicit preferences from patients in
OAT. The importance of this study is the achievement of patients’
preferences in a simply and well accepted method to allow plan-
ning optimal health care.
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OBJECTIVES: To compare costs associated with short (3-day)
versus standard (8-day) antibiotic therapy in hospitalised adult
patients with mild to moderate-severe community-acquired
pneumonia (CAP) in an economic evaluation as part of prospec-
tive double-blinded randomised controlled trial (RCT).
METHODS: Randomised, double blind, placebo-controlled
non-inferiority trial. Nine secondary and tertiary care hospitals
in the The Netherlands. A total of 186 adults with a mild to
moderate-severe CAP (pneumonia severity index £ 110). Patients
who had substantially improved after 72 hours (n = 119) were
randomly assigned to receive 5 days of either oral amoxicillin or
placebo thrice daily. Direct and indirect medical and non-medical
costs associated with resource utilisation during treatment and
follow-up until 28 days after randomisation. RESULTS: We ran-
domised 56 patients to placebo and 63 to active treatment.
Health outcomes in terms clinical success rates and symptom
recovery of were comparable in both study groups. The average
cumulative total costs generated during the ﬁrst 10 days (treat-
ment) were €3320 for standard versus €3352 for short antibiotic
treatment (€32 in favour of standard duration); during the
follow-up until day 28 these costs were €1072 versus €879,
respectively. The overall difference in costs was €159 in favour
of short therapy (€4391 versus €4232, respectively). CONCLU-
SIONS: Shorter antibiotic treatment is equally effective and does
not generate additional costs, as compared to standard treatment
in hospitalised patients with mild to moderate-severe CAP who
have substantially improved after three days of treatment.
Although clinical and economic outcomes for the individual
patient are comparable, the relevance of the ﬁndings concern the
societal level, as a potential reduction in the use of antibiotics
may slow down the development of antibiotic resistance and
need for costly development of new antibiotic therapies.
